{"entity":{"id":"clearnote-health","kind":"company","name":"ClearNote Health","aka":[],"tldr":"ClearNote Health sells blood tests that look for chemical marks on DNA fragments in the blood to catch pancreatic and ovarian cancer early in people at high risk.","summary":"ClearNote Health (formerly Bluestar Genomics) is a San Diego epigenomics company whose Avantect tests analyse cell-free DNA in plasma with a proprietary platform that captures epigenomic changes, combined with machine learning, to detect cancer signal in high-risk groups. The Avantect Pancreatic Cancer Test targets people with new-onset diabetes and other risk factors; an Avantect Ovarian Cancer Test and a multi-cancer detection programme are in development. The pancreatic test runs from a CLIA-certified, CAP-accredited laboratory, received a first in vitro diagnostic approval in July 2025 and a UK approval in September 2025, and validation data were shown at AACR, DDW and ASCO in 2026. In May 2026 the company closed a $52 million Series D led by founding investor Mattias Westman, with Sandy Weill and Stephen Quake participating, for over $185 million raised in total.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.clearnotehealth.com/"},{"label":"Series D press release (May 2026)","url":"https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/"},{"label":"Press release archive","url":"https://www.clearnotehealth.com/category/press-release/"}],"tags":[],"related":[],"cancers":["pancreatic","ovarian"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","methylation-profiling","mced"],"targets":[],"drugs":["avantect-mcd"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["vanguard-study"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Multi-cancer test (29 October 2026): the Avantect Multi-Cancer Detection Test, UKCA-marked in September 2025 by the company's account, is one of the two tests in the NCI Vanguard Study. The platform reads 5-hydroxymethylcytosine in cell-free DNA, as its peer-reviewed papers state (Chowdhury et al., J Mol Diagn 2024; Xue et al., Commun Biol 2025). Earlier rounds (Series B, C) not sourced. Founding year not sourced."],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://www.clearnotehealth.com/","stage":"growth","investors":[],"funding":[{"round":"Series D","year":2026,"amountUsd":52000000,"source":"https://www.clearnotehealth.com/clearnote-health-secures-52-million-in-series-d-financing-and-strengthens-leadership-team-to-accelerate-growth-in-early-cancer-detection/","note":"Led by founding investor Mattias Westman; cumulative funding stated as over $185 million."}]},"route":"/companies/clearnote-health/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"avantect-mcd","kind":"drug","name":"Avantect Multi-Cancer Detection Test","route":"/drugs/avantect-mcd/"}],"trial":[{"id":"clearnote-multi-cancer-epigenomics","kind":"trial","name":"ClearNote Health multi-cancer epigenomics study","route":"/trials/clearnote-multi-cancer-epigenomics/"},{"id":"inova-burn-pit-screening","kind":"trial","name":"Inova burn pit veterans cancer screening pilot","route":"/trials/inova-burn-pit-screening/"},{"id":"vanguard-study","kind":"trial","name":"Vanguard Study (NCI Cancer Screening Research Network)","route":"/trials/vanguard-study/"}]}}